You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 108 No. 3, Sept 1961 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (22)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Corticotropin in the Treatment of Tuberculosis

A Controlled Study

J. H. ANGEL, M.D., M.R.C.P.; L. S. CHU, M.D.; HAROLD A. LYONS, M.D.

Arch Intern Med. 1961;108(3):353-369.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Historical Introduction

Throughout the field of medicine, the use of corticotropin and the corticosteroid hormones has been controversial. This has especially been true in tuberculosis. The history of the use of the hormones in this disease falls into three phases. During the first phase, the hormones were used without any antituberculous therapy. This resulted in spread of active disease and reactivation of quiescent disease in tuberculous patients and the appearance of fresh disease in nontuberculous patients. This phase ended with the publication of the report of the Committee on Therapy of the American Trudeau Society (1952), which virtually placed an interdiction on the use of these hormones in tuberculosis. During the second phase, they were little used, especially in the United States. In Europe, some critically ill patients were treated with a combination of steroid hormones and antituberculous chemotherapy. Later, large numbers of patients treated with this combination were reported . . . [Full Text PDF of this Article]


Author Affiliations

BROOKLYN

Pulmonary Disease Division, Department of Medicine, Downstate Medical Center, State University of New York, Brooklyn.; Formerly Assistant Professor of Medicine, Downstate Medical Center, State University of New York; now at the Tuberculosis Research Unit, Medical Research Council, London England (Dr. Angel).


Footnotes

Submitted for publication June 7, 1960.

This study was aided by a contract with the United States Public Health Service, Tuberculosis Control Division, and the State University of New York, Downstate Medical Center.

This paper contains part of the material submitted as a Thesis for the Doctorate of Medicine and approved for the Raymond Horton-Smith prize at the University of Cambridge, England, by Dr. J. H. Angel.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1961 American Medical Association. All Rights Reserved.